Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totaling 398,714 shares, a growth of 217.0% from the August 15th total of 125,762 shares. Currently, 2.9% of the shares of the stock are short sold. Based on an average trading volume of 3,391,068 shares, the short-interest ratio is presently 0.1 days.

Catheter Precision Price Performance

Catheter Precision stock traded down $0.01 during trading hours on Monday, reaching $0.17. 453,158 shares of the stock were exchanged, compared to its average volume of 4,314,495. The company has a current ratio of 0.19, a quick ratio of 0.18 and a debt-to-equity ratio of 0.19. The company has a market cap of $2.40 million, a P/E ratio of -0.02 and a beta of -1.03. The stock has a 50 day moving average of $0.36 and a two-hundred day moving average of $0.82. Catheter Precision has a twelve month low of $0.16 and a twelve month high of $3.20.

Catheter Precision (NYSEAMERICAN:VTAK) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($19.00) by $18.08. Catheter Precision had a negative net margin of 656.03% and a negative return on equity of 37.53%. The business had revenue of $1.02 million for the quarter, compared to analysts’ expectations of $2.00 million.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.